176519-53-2

Basic information

• Product Name: Ethyl 2-(Methylethyl)-3-Oxo-4-Phenylbutyrate
• Synonyms: Ethyl 2-(Methylethyl)-3-Oxo-4-Phenylbutyrate;ETHYL 2-ISOPROPYL-3-OXO-4-PHENYLBUTANOATE
• CAS NO: 176519-53-2
• Molecular Formula: C₁₅H₂₀O₃
• Molecular Weight: 248.3175
• Mol File: 176519-53-2.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 328.2±17.0 °C(Predicted)
• Appearance: /
• Density: 1.038±0.06 g/cm3(Predicted)
• PKA: 12.08±0.46(Predicted)
• CAS DataBase Reference: Ethyl 2-(Methylethyl)-3-Oxo-4-Phenylbutyrate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl 2-(Methylethyl)-3-Oxo-4-Phenylbutyrate(176519-53-2)
• EPA Substance Registry System: Ethyl 2-(Methylethyl)-3-Oxo-4-Phenylbutyrate(176519-53-2)

Safety Data

• Hazardous Substances Data: 176519-53-2(Hazardous Substances Data)

Upstream product

• 718-08-1 ethyl 3-oxo-4-phenylbutyrate 
• 75-30-9 2-iodo-propane 
• 103-80-0 phenylacetyl chloride 
• 75-26-3 isopropyl bromide 
• 140-29-4 phenylacetonitrile 
• 609-12-1 ethyl 2-bromoisovalerate 

Downstream Products

• 176519-55-4 6-benzyl-5-isopropylpyrimidine-2,4(1H,3H)-dione 
• 199851-91-7 6-benzyl-5-isopropyl-2-thiouracil 
• 175739-42-1 6-benzyl-1-[(benzyloxy)methyl]-5-isopropylpyrimidine-2,4(1H,3H)-dione 
• 1254831-85-0 3-amino-6-benzyl-1-(benzyloxymethyl)-5-isopropylpyrimidine-2,4(1H,3H)-dione 
• 1254831-86-1 6-benzyl-1-(ethoxymethyl)-3-hydroxy-5-isopropylpyrimidine-2,4(1H,3H)-dione 
• 1254831-82-7 6-benzyl-1-((4-fluorobenzyloxy)methyl)-3-hydroxy-5-isopropylpyrimidine-2,4(1H,3H)-dione 
• 1254831-80-5 6-benzyl-1-(benzyloxymethyl)-3-hydroxy-5-isopropylpyrimidine-2,4(1H,3H)-dione 
• 1254831-91-8 6-benzyl-1-(((4-fluorobenzyl)oxy)methyl)-5-isopropylpyrimidine-2,4(1H,3H)-dione 
• 149950-60-7 Emivirine 

Relevant articles and documents

Synthesis and Antiviral Evaluation of 1-[(2-Phenoxyethyl)oxymethyl] and 6-(3,5-Dimethoxybenzyl) Analogues of HIV Drugs Emivirine and TNK-651

Novel emivirine analogues 6a, b were synthesized by reacting chloromethyl ethyl ether with 5-ethyl/isopropyl-6-(3,5-dimethoxybenzyl)uracils 5e, f. On the other hand, A series of new TNK-651 analogues 10a-f substituted at N-1 with phenoxyethoxymethyl moiety was prepared on treatment of the corresponding uracils 5a-f with bis(phenoxyethoxy)methane (9). The newly synthesized non-nucleosides were tested for antiviral activity against wild type HIV-1 IIIB as well as the resistant strains N119 (Y181C), A17 (K103N+Y181C), and the triple mutant EFVR (K103R+V179D+P225H) in MT-4 cells. Most of the tested compounds showed good activities. Among them 6-(3,5-dimethylbenzyl)-5-ethyl-1-[(2-phenoxyethyl)oxymethyl]uracil (10c) and 6-(3,5-dimethylbenzyl)-5-isopropyl-1-[(2-phenoxyethyl)oxymethyl]uracil (10d) that showed inhibitory potency higher than emivirine against both wild type HIV-1 and the tested mutant strains, as well as higher activity than efavirenz against EFVR.

N-3 hydroxylation of pyrimidine-2,4-diones yields dual inhibitors of HIV reverse transcriptase and integrase

A new molecular scaffold featuring an N-hydroxyimide functionality and capable of inhibiting both reverse transcriptase (RT) and integrase (IN) of human immunodeficiency virus (HIV) was rationally designed based on 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) non-nucleoside RT inhibitors (NNRTIs). The design involves a minimal 3-N hydroxylation of the pyrimidine ring of HEPT compound to yield a chelating triad which, along with the existing benzyl group, appeared to satisfy major structural requirements for IN binding. In the mean time, this chemical modification did not severely compromise the compound's ability to inhibit RT. A preliminary structure-activity relationship (SAR) study reveals that this N-3 OH is essential for IN inhibition and that the benzyl group on N-1 side chain is more important for IN binding than the one on C-6.

Phenethyl-5-bromopyridylthiourea (PBT) and dihydroalkoxybenzyloxopyrimidine (DABO) derivatives exhibiting spermicidal activity

Novel phenethyl-5-bromopyridylthiourea (PBT) and dihydroalkoxybenzyloxopyrimidine (DABO) derivatives exhibiting spermicidal activity as well as anti-viral activity. These novel compounds can be incorporated within contraceptive compositions to provide for